永安藥業(002365.SZ):取得2項實用新型專利證書
格隆匯12月15日丨永安藥業(002365.SZ)公佈,近日,公司收到國家知識產權局頒發的兩項實用新型專利證書,分別為一種高效去除羥乙基磺酸鹽中硫酸根的生產裝置、一種去除羥乙基磺酸鹽中硫酸根的處理裝置。
公司為全球牛磺酸領域的知名企業,一直致力於牛磺酸生產技術的研發及其技術儲備,不斷優化和提升牛磺酸生產工藝,使公司持續在牛磺酸領域保持技術領先優勢。本次實用新型專利的取得有利於公司加強專利技術保護,充分發揮公司主導產品自主知識產權優勢,不斷提升公司核心競爭力。本次實用新型專利的取得暫不會對公司生產經營和業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.